Tesevatinib

Tesevatinib
Clinical data
Routes of
administration		 Oral administration (tablets)
Pharmacokinetic data
Elimination half-life 50–70 hours
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
Formula C24H25Cl2FN4O2
Molar mass 491.3919 g/mol
3D model (JSmol)

Tesevatinib (KD019, XL647) is an experimental drug proposed for use in kidney cancer and polycystic kidney disease. The drug was first developed by Exelixis, Inc.[1] and was later acquired by Kadmon Corporation. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4).[2]

The drug activity was initially studied in non-small cell lung cancer.[3] In a 2007 pre-clinical study with xenograft tumors of an erlotinib-resistant cell line tesevatinib substantially inhibited the growth of these tumors.[4] In polycystic kidney disease, a histological study of the drug effects and toxicity in rats and mice was published in July 2017.[5]

As of July 2018 the drug was in Phase II clinical trials for the treatment of polycystic kidney disease in adults and children.[6]

References

  1. ↑ Gendreau, Steven B.; et al. (June 15, 2007). "Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647". Clin. Cancer Res. 13 (12): 3713–3723. doi:10.1158/1078-0432.CCR-06-2590. Retrieved 30 October 2017.
  2. ↑ "Substance Name: Tesevatinib [USAN:INN]". US National Library of Medicine. Retrieved 30 October 2017. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
  3. ↑ Carrizosa, MD, Daniel R.; et al. "New Targets and New Mechanisms in Lung Cancer (May 15, 2013)". CancerNetwork. UBM Medica, LLC,. Retrieved 30 October 2017.
  4. ↑ Gendreau, Steven B.; et al. (June 15, 2007). "Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647". Clinical Cancer Research. 13 (12): 3713–23. doi:10.1158/1078-0432.CCR-06-2590. PMID 17575237. Retrieved 30 October 2017.
  5. ↑ Sweeney, William E.; Frost, Philip; et al. (July 6, 2017). "Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease". World Journal of Nephrology. 6 (4): 188–200. doi:10.5527/wjn.v6.i4.188. PMC 5500456.
  6. ↑ "ClinicalTrials.gov - Tesevatinib". US National Library of Medicine. Retrieved 27 July 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.